Neima Briggs, MD, PhD
Clinical FellowAbout
Titles
Clinical Fellow
Biography
Dr. Briggs is a physician-scientist at Yale University. He is a clinical instructor in the Department of Internal Medicine (Infectious Diseases) and a postdoctoral fellow in the Department of Immunobiology. His lab studies immunity to parasitic infections and works closely with the Craft Lab at Yale, Texas Children's Hospital Center for Vaccine Development, and the Fujiwara Lab at the Federal University of Minas Gerais.
Dr. Briggs provides subspecialty outpatient care in Travel and Tropical Medicine at Yale and West Haven VA.
Appointments
Infectious Diseases
Clinical FellowPrimaryInfectious Diseases
InstructorSecondary
Other Departments & Organizations
Education & Training
- Resident
- Yale University (2021)
- MD
- The University of Texas Medical School at Houston (2019)
- PhD
- The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Immunology (2018)
- DTM&H
- Baylor College of Medicine, The National School of Tropical Medicine (2018)
- BS
- The University of Texas at Austin (2011)
Research
Publications
2024
The amalgam of naive CD4+ T cell transcriptional states is reconfigured by helminth infection to dampen the amplitude of the immune response
Even Z, Meli A, Tyagi A, Vidyarthi A, Briggs N, de Kouchkovsky D, Kong Y, Wang Y, Waizman D, Rice T, De Kumar B, Wang X, Palm N, Craft J, Basu M, Ghosh S, Rothlin C. The amalgam of naive CD4+ T cell transcriptional states is reconfigured by helminth infection to dampen the amplitude of the immune response. Immunity 2024, 57: 1893-1907.e6. PMID: 39096910, DOI: 10.1016/j.immuni.2024.07.006.Peer-Reviewed Original ResearchT cell receptorImmune responseNaive CD4<sup>+</sup> T cellsCD4<sup>+</sup> T cellsIFN-IHelminth infectionsNippostrongylus brasiliensis infectionDecreased immune responseType I interferonNaive TT cellsMemory-likeUnrelated antigensTranscriptional changesExtracellular matrixSPF miceCell receptorsI interferonGerm-freeResponse to certain environmental cuesInfectionMiceFunctional changesCell transcriptional statesTranscriptional heterogeneity
2023
Response to comment on “Dosing implications for liposomal amphotericin B in pregnancy”
O'Grady N, Davis M, McManus D, Topal J, Azar M, Briggs N. Response to comment on “Dosing implications for liposomal amphotericin B in pregnancy”. Pharmacotherapy The Journal Of Human Pharmacology And Drug Therapy 2023, 43: 992-992. PMID: 37701938, DOI: 10.1002/phar.2864.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDosing implications for liposomal amphotericin B in pregnancy
O'Grady N, McManus D, Briggs N, Azar M, Topal J, Davis M. Dosing implications for liposomal amphotericin B in pregnancy. Pharmacotherapy The Journal Of Human Pharmacology And Drug Therapy 2023, 43: 452-462. PMID: 36862037, DOI: 10.1002/phar.2784.Peer-Reviewed Original ResearchConceptsIdeal body weightLiposomal amphotericin BMucocutaneous leishmaniasisBody weightAmphotericin BInfectious Diseases SocietyTotal body weightPregnant patientsDiseases SocietyAmerica guidelinesPreferred agentPregnancyParasitic infectionsOpportunistic fungalAdverse effectsPatientsTreatmentLeishmaniasisLambsDaysUse of lambsGuidelinesRegimensWeightFetuses
2022
Mucocutaneous Leishmaniasis in a Pregnant Immigrant
Briggs N, Wei BM, Ahuja C, Baker C, Palacios C, Lee E, O’Grady N, Singanamala S, Singh K, Bandaranayake TD, Cohen JM, Damsky W, Davis MW, Mejia R, Nelson CA, Topal JE, Azar MM. Mucocutaneous Leishmaniasis in a Pregnant Immigrant. Open Forum Infectious Diseases 2022, 9: ofac360. PMID: 35928503, PMCID: PMC9345408, DOI: 10.1093/ofid/ofac360.Peer-Reviewed Original ResearchEfficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.Peer-Reviewed Original ResearchConceptsCCP recipientsPlacebo recipientsSecondary outcomesSymptom durationHospitalized patientsPrimary outcomeDay 28COVID-19SARS-CoV-2 serostatusSARS-CoV-2 titersWorld Health Organization (WHO) ordinal scaleCOVID-19 convalescent plasmaConvalescent plasma usePlacebo-controlled trialLess daysExploratory subgroup analysisNon-Hispanic blacksSARS-CoV-2CCP efficacyConcomitant medicationsAdverse eventsClinical improvementSymptom onsetConvalescent plasmaMedian age
2021
Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere disease
2020
Advances in rapid diagnostics for bloodstream infections
Briggs N, Campbell S, Gupta S. Advances in rapid diagnostics for bloodstream infections. Diagnostic Microbiology And Infectious Disease 2020, 99: 115219. PMID: 33059201, DOI: 10.1016/j.diagmicrobio.2020.115219.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2018
Trichuris muris whey acidic protein induces type 2 protective immunity against whipworm
Briggs N, Wei J, Versteeg L, Zhan B, Keegan B, Damania A, Pollet J, Hayes KS, Beaumier C, Seid CA, Leong J, Grencis RK, Bottazzi ME, Sastry KJ, Hotez PJ. Trichuris muris whey acidic protein induces type 2 protective immunity against whipworm. PLOS Pathogens 2018, 14: e1007273. PMID: 30153307, PMCID: PMC6130879, DOI: 10.1371/journal.ppat.1007273.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseImmune correlatesLymph nodesProtective immunityT helper type 2 immune responseT. murisType 2 immune responsesIgE-mediated allergic responsesTh2 cytokines IL-4Adult T. murisAntigen-specific productionCellular immune correlatesHumoral immune correlatesMesenteric lymph nodesInguinal lymph nodesMontanide ISA 720Cytokines IL-4Control of infectionLow drug efficacySubcutaneous vaccineBowel diseaseInfectious causesOral challengeISA 720Protective efficacy
2017
Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response
Wei J, Versteeg L, Liu Z, Keegan B, Gazzinelli-Guimarães AC, Fujiwara RT, Briggs N, Jones KM, Strych U, Beaumier CM, Bottazzi ME, Hotez PJ, Zhan B. Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response. PLOS Neglected Tropical Diseases 2017, 11: e0005769. PMID: 28708895, PMCID: PMC5529013, DOI: 10.1371/journal.pntd.0005769.Peer-Reviewed Original ResearchConceptsTh2-skewed immune responseTh2-type responseCholera toxin B subunitImmune responseEgg challengeProtective immunitySignificant protectionPredominant Th2-type responseTh2-type immune responseFeasible vaccine candidateTh1-type responseCommon helminth infectionA. suum infectionAscaris suum infectionExact protective mechanismHost immune systemToxin B subunitA. suumRestimulated splenocytesA. suum eggsChallenge infectionIL-4IL-5Trichuris infectionHelminth infections
2016
The Hygiene Hypothesis and Its Inconvenient Truths about Helminth Infections
Briggs N, Weatherhead J, Sastry KJ, Hotez PJ. The Hygiene Hypothesis and Its Inconvenient Truths about Helminth Infections. PLOS Neglected Tropical Diseases 2016, 10: e0004944. PMID: 27632204, PMCID: PMC5025185, DOI: 10.1371/journal.pntd.0004944.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
News & Links
News
- November 20, 2023
Fellow Focus in Four: Neima Briggs, MD, PhD, Infectious Diseases
- June 05, 2023
Discoveries & Impact (June 2023)
- August 11, 2021
Discoveries & Impact (August 2021)